---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000230"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:27:00.601023+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KalVista promotes CFO/CBO Palleiko to President; cites $190M cash for sebetralstat launch prep

## Summary
- Benjamin L. Palleiko appointed President effective Jan 4, 2023, while retaining CFO and CBO roles.
- Promotion follows $58M registered direct offering in Dec 2022 at 17% premium; pro forma cash ~$190M.
- Palleiko to lead commercial organization for planned launch of sebetralstat, an oral HAE therapy in Phase 3.
- KalVista expects KONFIDENT Phase 3 data in H2 2023 and NDA filing in H1 2024; cash runway into 2025.

## SEC filing metadata
- accession: 0000950170-23-000230
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017023000230/0000950170-23-000230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017023000230/kalv-20230104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000230
- JSON: https://secwatch.observer/filing/0000950170-23-000230.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000230.txt

## Key facts
- Executive change
  Benjamin L. Palleiko was appointed as President at KalVista Pharmaceuticals, Inc..
  - Action: appointed
  - Role: President
  source text: On January 4, 2023, KalVista Pharmaceuticals, Inc. (the “Company”) announced the appointment of Benjamin L. Palleiko, currently the Company’s Chief Business Officer and Chief Financial Officer, to the position of President of the Company, effective as of January 4, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023000230/0000950170-23-000230-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.